Cargando…

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.

Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CB10-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for antitumour activity. In preclinical models (human mel...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, B. J., Newell, D. R., Carmichael, J., Harris, A. L., Gumbrell, L. A., Jones, M., Goodard, P. M., Calvert, A. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968184/
https://www.ncbi.nlm.nih.gov/pubmed/8431367
_version_ 1782134685309075456
author Foster, B. J.
Newell, D. R.
Carmichael, J.
Harris, A. L.
Gumbrell, L. A.
Jones, M.
Goodard, P. M.
Calvert, A. H.
author_facet Foster, B. J.
Newell, D. R.
Carmichael, J.
Harris, A. L.
Gumbrell, L. A.
Jones, M.
Goodard, P. M.
Calvert, A. H.
author_sort Foster, B. J.
collection PubMed
description Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CB10-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for antitumour activity. In preclinical models (human melanoma xenografts and transplantable rodent tumours) CB10-277 showed a similar spectrum and level of activity when compared to dacarbazine. Pharmacokinetic studies were performed with CB10-277 in mice treated i.v. at the LD10 (750 mg m-2) and plasma analysed by HPLC. The parent drug area under the plasma concentration vs time curve (AUC) was 142 mM x minutes. Drug metabolism occurred as evidenced by the HPLC identification of the monomethyl species (AUC = 8 mM x minutes) as well as other metabolites. A Phase I trial using a short infusion with doses repeated every 21 days has been performed. Thirty-six patients received 80 courses over a dose range of 80-6,000 mg m-2. The dose limiting toxicity was nausea and vomiting which occurred in 80% of the evaluable courses > or = 900 mg m-2. The only other common side effect was a flushing or warm sensation, which occurred in over 75% of courses at > or = 1,350 mg m-2. There were no hemodynamic consequences. Responses occurred in patients with melanoma (one complete, two partial, one mixed/11), sarcoma (one mixed/6) and carcinoid (one partial/l). Pharmacokinetics were performed in 46 courses. The CB10-277 AUC increased linearly with dose (r = 0.9203, P < 0.001) up to 700 mM x minutes at 6,000 mg m-2). Evidence of CB10-277 metabolism was observed, as in mice, by detection of the monomethyl species and other metabolites. However, the plasma levels of the monomethyl species in patients (1.8 and 3.7 mM x minutes at 6,000 mg m-2) were less than those predicted from studies in mice. Despite this, antitumour activity in dacarbazine sensitive histologies was observed and additional studies with CB10-277 are recommended.
format Text
id pubmed-1968184
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19681842009-09-10 Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Foster, B. J. Newell, D. R. Carmichael, J. Harris, A. L. Gumbrell, L. A. Jones, M. Goodard, P. M. Calvert, A. H. Br J Cancer Research Article Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CB10-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for antitumour activity. In preclinical models (human melanoma xenografts and transplantable rodent tumours) CB10-277 showed a similar spectrum and level of activity when compared to dacarbazine. Pharmacokinetic studies were performed with CB10-277 in mice treated i.v. at the LD10 (750 mg m-2) and plasma analysed by HPLC. The parent drug area under the plasma concentration vs time curve (AUC) was 142 mM x minutes. Drug metabolism occurred as evidenced by the HPLC identification of the monomethyl species (AUC = 8 mM x minutes) as well as other metabolites. A Phase I trial using a short infusion with doses repeated every 21 days has been performed. Thirty-six patients received 80 courses over a dose range of 80-6,000 mg m-2. The dose limiting toxicity was nausea and vomiting which occurred in 80% of the evaluable courses > or = 900 mg m-2. The only other common side effect was a flushing or warm sensation, which occurred in over 75% of courses at > or = 1,350 mg m-2. There were no hemodynamic consequences. Responses occurred in patients with melanoma (one complete, two partial, one mixed/11), sarcoma (one mixed/6) and carcinoid (one partial/l). Pharmacokinetics were performed in 46 courses. The CB10-277 AUC increased linearly with dose (r = 0.9203, P < 0.001) up to 700 mM x minutes at 6,000 mg m-2). Evidence of CB10-277 metabolism was observed, as in mice, by detection of the monomethyl species and other metabolites. However, the plasma levels of the monomethyl species in patients (1.8 and 3.7 mM x minutes at 6,000 mg m-2) were less than those predicted from studies in mice. Despite this, antitumour activity in dacarbazine sensitive histologies was observed and additional studies with CB10-277 are recommended. Nature Publishing Group 1993-02 /pmc/articles/PMC1968184/ /pubmed/8431367 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Foster, B. J.
Newell, D. R.
Carmichael, J.
Harris, A. L.
Gumbrell, L. A.
Jones, M.
Goodard, P. M.
Calvert, A. H.
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
title Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
title_full Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
title_fullStr Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
title_full_unstemmed Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
title_short Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
title_sort preclinical, phase i and pharmacokinetic studies with the dimethyl phenyltriazene cb10-277.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968184/
https://www.ncbi.nlm.nih.gov/pubmed/8431367
work_keys_str_mv AT fosterbj preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277
AT newelldr preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277
AT carmichaelj preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277
AT harrisal preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277
AT gumbrellla preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277
AT jonesm preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277
AT goodardpm preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277
AT calvertah preclinicalphaseiandpharmacokineticstudieswiththedimethylphenyltriazenecb10277